Extended Data Fig. 1: Tc9 cells control the outgrowth of natural ALV tumors.

a, MFI of OVA-GFP and OVA (SIINFEKL) on WT B16 and B16^OVA cells (n = 3 technical replicates from a single experiment, repeated two times with similar results). b, Western blot detection of OVA in B16 and B16^OVA cells (one of two independent experiments). c, Schema of experiments in Fig. 1a. d, Schema of experiments in Fig. 1b. e, Western blot and flow cytometry (n = 3 technical replicates from a single experiment, repeated two times with similar results) detection of gp100 in MC38 and MC38^gp100 cells. f, Schema of experiments in Extended Data Fig. 1g. g, PBS, Thy1.1⁺ Pmel-1 Tc1 or Tc9 cells were transferred into CD45.2⁺ B6 mice bearing MC38^gp100 tumors with the adjuvant treatment, and tumor growth curves were shown (n = 5 mice per group, one of two independent experiments). h. Percentages of OVA-GFP^negative and OVA-GFP^positive CD45⁻ tumor cells on day 10 (n = 3 mice) and day 40 (n = 4 mice) after B16^OVA tumor inoculation (one of two independent experiments). i. Percentages of gp100^negative and gp100^positive CD45⁻ tumor cells on Day 10 and Day 40 after MC38^gp100 tumor inoculation (n = 5 mice per group). Data are presented as mean ± SEM. Two-way ANOVA was used to compare antigen percentages in h, i. neg, negative; pos, positive.

Source data